Yujian Yang

Structure-Based Design and Optimization of Onradivir-Derived PB2 Inhibitors for the Treatment of Influenza A.

Influenza A remains a major seasonal public health burden. With the approval of onradivir, PB2 has emerged as an attractive antiviral target due to its unique and conserved structural features. Herein, using onradivir as the lead, we employed bioisosteric replacement strategies to design a series of derivatives for SAR...